Header Logo

Connection

HANA EL SAHLY to Female

Back to Details
This is a "connection" page, showing publications HANA EL SAHLY has written about Female.
HANA EL SAHLY
Connection Strength
0.536
Female
  1. A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples. J Infect Dis. 2026 Mar 17; 233(3):e646-e650.
    View in: PubMed
    Score: 0.038
  2. Central Nervous System Histoplasmosis: A Retrospective Review of Clinical Characteristics, Treatments and Outcomes With Comparison to Disseminated Histoplasmosis Without Central Nervous System Involvement. Mycoses. 2025 May; 68(5):e70068.
    View in: PubMed
    Score: 0.036
  3. CD8 Encephalitis in a Treatment-Naive and a Virologically Suppressed Patient with HIV. Can J Neurol Sci. 2019 11; 46(6):773-775.
    View in: PubMed
    Score: 0.025
  4. Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. Vaccine. 2019 05 01; 37(19):2561-2568.
    View in: PubMed
    Score: 0.024
  5. Performance of Xpert MTB/RIF in induced sputum samples at detecting Mycobacterium tuberculosis. Clin Infect Dis. 2014 Sep 15; 59(6):911-2.
    View in: PubMed
    Score: 0.017
  6. Mycobacterium tuberculosis bacteraemia: experience from a non-endemic urban centre. Clin Microbiol Infect. 2014 Mar; 20(3):263-8.
    View in: PubMed
    Score: 0.016
  7. Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. J Infect Dis. 2012 Mar 01; 205(5):703-12.
    View in: PubMed
    Score: 0.014
  8. Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas. J Clin Microbiol. 2011 Aug; 49(8):2942-5.
    View in: PubMed
    Score: 0.014
  9. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev Vaccines. 2010 Oct; 9(10):1135-41.
    View in: PubMed
    Score: 0.013
  10. Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic. Clin Vaccine Immunol. 2010 Oct; 17(10):1552-9.
    View in: PubMed
    Score: 0.013
  11. Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. Vaccine. 2009 Aug 06; 27(36):4905-11.
    View in: PubMed
    Score: 0.012
  12. A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults. J Infect Dis. 2026 Mar 17; 233(3):e641-e645.
    View in: PubMed
    Score: 0.010
  13. Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials. Vaccine. 2026 Apr 02; 77:128380.
    View in: PubMed
    Score: 0.010
  14. Validating and leveraging non-SARS-CoV-2 respiratory infection as a negative control outcome in a phase 3 COVID-19 vaccine trial with extended observational follow-up. Am J Epidemiol. 2026 Jan 08; 195(1):168-177.
    View in: PubMed
    Score: 0.009
  15. Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination. Vaccine. 2026 Jan 01; 69:127959.
    View in: PubMed
    Score: 0.009
  16. Drug-resistant tuberculosis: a disease of target populations in Houston, Texas. J Infect. 2006 Jul; 53(1):5-11.
    View in: PubMed
    Score: 0.009
  17. Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine. J Infect Dis. 2025 Oct 15; 232(4):971-981.
    View in: PubMed
    Score: 0.009
  18. Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59?. Vaccine. 2025 02 15; 47:126702.
    View in: PubMed
    Score: 0.009
  19. Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials. J Infect Dis. 2024 Dec 16; 230(6):1384-1389.
    View in: PubMed
    Score: 0.009
  20. Postnatal Zika and Dengue Infection and their Effects on Neurodevelopment Among Children Living in Rural Guatemala. Pediatr Infect Dis J. 2025 Apr 01; 44(4):290-298.
    View in: PubMed
    Score: 0.009
  21. Evaluation of Vancomycin Dose Needed to Achieve 24-Hour Area Under the Concentration-Time Curve to Minimum Inhibitory Concentration Ratio Greater Than or Equal to 400 Using Pharmacometric Approaches in Pediatric Intensive Care Patients. Crit Care Explor. 2024 Oct 01; 6(10):e1159.
    View in: PubMed
    Score: 0.009
  22. SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir. J Infect Dis. 2024 Sep 23; 230(3):624-634.
    View in: PubMed
    Score: 0.009
  23. Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial. Nat Commun. 2024 09 11; 15(1):7954.
    View in: PubMed
    Score: 0.009
  24. Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases. Nat Commun. 2024 Aug 29; 15(1):7469.
    View in: PubMed
    Score: 0.009
  25. COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials. Clin Infect Dis. 2024 08 16; 79(2):364-374.
    View in: PubMed
    Score: 0.009
  26. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 06 14; 78(6):1757-1768.
    View in: PubMed
    Score: 0.008
  27. SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials. JAMA Netw Open. 2024 05 01; 7(5):e2412835.
    View in: PubMed
    Score: 0.008
  28. The effect of mannose binding lectin gene polymorphisms on susceptibility to tuberculosis in different ethnic groups. Scand J Infect Dis. 2004; 36(2):106-8.
    View in: PubMed
    Score: 0.008
  29. Identification of immunodominant T cell epitopes induced by natural Zika virus infection. Front Immunol. 2023; 14:1247876.
    View in: PubMed
    Score: 0.008
  30. Challenges and lessons learned from the rapid operationalization of a prospective cohort to study the natural history and neurodevelopmental outcomes of postnatal Zika virus infection among infants and children in rural Guatemala. PLoS Negl Trop Dis. 2022 11; 16(11):e0010480.
    View in: PubMed
    Score: 0.008
  31. Mycobacterium simiae pseudo-outbreak resulting from a contaminated hospital water supply in Houston, Texas. Clin Infect Dis. 2002 Oct 01; 35(7):802-7.
    View in: PubMed
    Score: 0.007
  32. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022 09; 10(9):888-899.
    View in: PubMed
    Score: 0.007
  33. Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med. 2022 03 17; 386(11):1046-1057.
    View in: PubMed
    Score: 0.007
  34. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022 Jan 07; 375(6576):43-50.
    View in: PubMed
    Score: 0.007
  35. Sensitive and Prolonged Detection of Dengue Virus RNA in Whole Blood. Am J Trop Med Hyg. 2021 03 22; 104(5):1734-1736.
    View in: PubMed
    Score: 0.007
  36. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 02 04; 384(5):403-416.
    View in: PubMed
    Score: 0.007
  37. Epidemiologic differences between United States- and foreign-born tuberculosis patients in Houston, Texas. J Infect Dis. 2001 Feb 01; 183(3):461-8.
    View in: PubMed
    Score: 0.007
  38. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 03 04; 384(9):795-807.
    View in: PubMed
    Score: 0.007
  39. Reliability and Validity of an Adapted and Translated Version of the Mullen Scales of Early Learning (AT-MSEL) in Rural Guatemala. Child Care Health Dev. 2020 05; 46(3):327-335.
    View in: PubMed
    Score: 0.006
  40. A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area. Vaccine. 2019 10 08; 37(43):6500-6509.
    View in: PubMed
    Score: 0.006
  41. Receptive language skills among young children in rural Guatemala: The relationship between the Test de Vocabulario en Imagenes Peabody and a translated and adapted version of the Mullen Scales of Early Learning. Child Care Health Dev. 2019 09; 45(5):702-708.
    View in: PubMed
    Score: 0.006
  42. Optimizing PCR Detection of Zika Virus from Various Body Fluids. Am J Trop Med Hyg. 2019 02; 100(2):427-433.
    View in: PubMed
    Score: 0.006
  43. Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74?years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2018 01 29; 36(5):606-614.
    View in: PubMed
    Score: 0.005
  44. Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial. Vaccine. 2017 08 24; 35(36):4730-4737.
    View in: PubMed
    Score: 0.005
  45. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. Vaccine. 2017 03 23; 35(13):1675-1682.
    View in: PubMed
    Score: 0.005
  46. Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial. Vaccine. 2017 02 07; 35(6):923-928.
    View in: PubMed
    Score: 0.005
  47. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015 Jul 21; 314(3):237-46.
    View in: PubMed
    Score: 0.005
  48. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-na?ve subjects. Vaccine. 2015 Sep 22; 33(39):5225-34.
    View in: PubMed
    Score: 0.005
  49. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine. 2015 Jan 01; 33(1):163-73.
    View in: PubMed
    Score: 0.004
  50. Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults. Vaccine. 2014 Oct 29; 32(47):6284-93.
    View in: PubMed
    Score: 0.004
  51. Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial. Vaccine. 2014 Feb 12; 32(8):1019-28.
    View in: PubMed
    Score: 0.004
  52. Rapid research response to the 2009 A(H1N1)pdm09 influenza pandemic (Revised). BMC Res Notes. 2013 May 03; 6:177.
    View in: PubMed
    Score: 0.004
  53. Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis. 2012 Oct 01; 206(7):1069-77.
    View in: PubMed
    Score: 0.004
  54. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok?) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine. 2011 Oct 13; 29(44):7733-9.
    View in: PubMed
    Score: 0.003
  55. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine. 2011 Oct 06; 29(43):7357-63.
    View in: PubMed
    Score: 0.003
  56. A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine. 2010 Apr 09; 28(17):3025-9.
    View in: PubMed
    Score: 0.003
  57. Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults. Hum Vaccin. 2009 Aug; 5(8):536-44.
    View in: PubMed
    Score: 0.003
  58. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA. 2008 Oct 01; 300(13):1532-43.
    View in: PubMed
    Score: 0.003
  59. 5' dinucleotide repeat polymorphism of NRAMP1 and susceptibility to tuberculosis among Caucasian patients in Houston, Texas. Int J Tuberc Lung Dis. 2002 Sep; 6(9):818-23.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.